-
Posted by
Two Blokes Jun 23 -
Filed in
Stock
-
3 views
Head-to-head study comparing BioREtain \u00ae - processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that patient enrollment has been completed in the Company's clinical trial evaluating BioREtain\u00ae Amnion Chorion (BR-AC) versus standard of care for patients with non-healing diabetic foot ulcers (DFUs).
